biotech · Type 1 Diabetes · Coronavirus · SABS
SAB Biotherapeutics
SAB Biotherapeutics clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Gaithersburg, USA
- Founded
- 2016
- Employees
- 39
- Programs
- 8
- Drugs
- 10
- Patents
- 1
SAB Biotherapeutics projects
8 ClinicalTrials.gov programs sponsored by SAB Biotherapeutics.
SAB Biotherapeutics has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
bamlanivimab 7000mg
SAB Biotherapeutics
Coronavirus
1 trial -
High Dose SAB-142
SAB Biotherapeutics
Type 1 Diabetes
1 trial -
SAB-142, SODIUM CHLORIDE
SAB Biotherapeutics
Type 1 Diabetes
1 trial -
SAB-176
SAB Biotherapeutics
Influenza A H1N1
1 trial -
SAB-176
SAB Biotherapeutics
Influenza Type A
1 trial -
SAB-185
SAB Biotherapeutics
COVID-19
2 trials -
SAB-301
SAB Biotherapeutics
Middle East Respiratory Syndrome Coronavirus
1 trial -
Single Ascending Dose of SAB-176
SAB Biotherapeutics
PHA1A
1 trial
Frequently asked questions
How many clinical projects does SAB Biotherapeutics have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.